ACADIA Pharmaceuticals, Inc. (ACAD) Announces Completion of Enrollment in Phase III Pimavanserin Trial in Parkinson’s Disease Psychosis
9/5/2012 10:11:04 AM
SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced the completion of enrollment in its ongoing pivotal Phase III trial with pimavanserin in patients with Parkinson’s disease psychosis (PDP). Top-line results from this trial are expected to be announced by the end of November 2012.
comments powered by